v3.26.1
Summary of Significant Accounting Policies - Segments (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Summary of Significant Accounting Policies            
Number of reportable segments | segment         1  
Number of operating segments | segment         1  
Operating expenses:            
General and administrative $ 18,573   $ 15,741   $ 41,445 $ 29,185
Total operating expenses 118,630   70,451   208,009 126,762
Loss from operations (118,630)   (70,451)   (208,009) (126,762)
Interest and other income, net 12,705   8,929   26,306 18,505
Loss before provision for income taxes (105,925)   (61,522)   (181,703) (108,257)
Provision for income taxes 234   139   424 237
Net loss attributable to ordinary shareholders (106,159) $ (75,968) (61,661) $ (46,833) (182,127) (108,494)
Single Reporting Segment            
Operating expenses:            
Discovery research and development 23,079   26,244   41,596 48,031
Manufacturing 15,278   133   19,548 133
Clinical research and development 49,859   23,016   85,055 40,173
Other research and development expenses 11,841   5,317   20,365 9,240
General and administrative 18,573   15,741   41,445 29,185
Total operating expenses 118,630   70,451   208,009 126,762
Loss from operations (118,630)   (70,451)   (208,009) (126,762)
Interest and other income, net 12,705   8,929   26,306 18,505
Loss before provision for income taxes (105,925)   (61,522)   (181,703) (108,257)
Provision for income taxes 234   139   424 237
Net loss attributable to ordinary shareholders $ (106,159)   $ (61,661)   $ (182,127) $ (108,494)